tiprankstipranks
Relay Therapeutics (RLAY)
NASDAQ:RLAY
US Market
Holding RLAY?
Track your performance easily

Relay Therapeutics (RLAY) Ownership - Who Owns Relay Therapeutics?

406 Followers

Relay Therapeutics (RLAY) Ownership Overview

3.00%14.94%51.61%14.12%16.33%
51.61% Other Institutional Investors
14.12% ETFs
16.33% Public Companies and
Individual Investors
The ownership structure of Relay Therapeutics (RLAY) stock is a mix of institutional, retail, and individual investors. Approximately 80.67% of the company’s stock is owned by Institutional Investors, 3.00% is owned by Insiders, and 16.33% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 30, 2024
xxxxxxxxxxxxx
$9890
Oct 30, 2024
xxxxxxxxxxxxx
$10284
Oct 30, 2024
Donald A Bergstrom
President, R&d
xxxxxxxxxxxxx
$16289
Oct 30, 2024
Peter Rahmer
Chief Corporate Development Officer
xxxxxxxxxxxxx
$9823

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$70800
Sep 30, 2024
xxxxxxxxxxxxx
$186685
Sep 30, 2024
xxxxxxxxxxxxx
$1960480

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
13,716,643Institution8.19%65,154,054
10,282,812Institution6.14%48,843,357
5,159,041Institution3.08%24,505,445
2,128,033Insider1.27%10,108,157
2,073,166Institution1.24%9,847,539
2,067,484Institution1.24%9,820,549
1,613,462Institution0.96%7,663,945
1,214,260Institution0.73%5,767,735
1,160,117Institution0.69%5,510,556
1,147,502Institution0.69%5,450,635

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
10,282,812Institution6.14%48,843,357
2,073,166Institution1.24%9,847,539
1,613,462Institution0.96%7,663,945
1,214,260Institution0.73%5,767,735
1,147,502Institution0.69%5,450,635
1,025,770Institution0.61%4,872,408
992,831Institution0.59%4,715,947
781,324Institution0.47%3,711,289
573,034Institution0.34%2,721,912
568,998Institution0.34%2,702,741

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
4,897,215Institution2.93%27,595,807
3,876,480Institution2.32%21,843,965
2,721,827Institution1.63%12,928,678
2,131,716Institution1.27%12,012,220
1,887,939Institution1.13%10,638,536
1,908,802Institution1.14%8,856,841
961,939Institution0.57%4,569,210
773,788Institution0.46%3,675,493
609,006Institution0.36%2,825,788
452,309Institution0.27%2,548,761

FAQ

Who Owns Relay Therapeutics (RLAY)?
According to the latest TipRanks data, approximately 51.61% of the company's stock is held by institutional investors, 3.00% is held by insiders, and 16.33% is held by retail investors.
    What percentage of Relay Therapeutics (RLAY) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 51.61% of Relay Therapeutics (RLAY) stock is held by institutional investors.
      What percentage of Relay Therapeutics (RLAY) stock is held by retail investors?
      According to the latest TipRanks data, approximately 16.33% of Relay Therapeutics (RLAY) stock is held by retail investors.
        Who owns the most shares of Relay Therapeutics (RLAY)?
        Vanguard owns the most shares of Relay Therapeutics (RLAY).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis